Research Topics
Species | MICHAEL J O'NEILLSummaryAffiliation: Eli Lilly and Company Country: USA Publications
| Collaborators
|
Detail Information
Publications
AMPA receptor potentiators: application for depression and Parkinson's diseaseMICHAEL J O'NEILL
Eli Lilly and Co Ltd, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, UK
Curr Drug Targets 8:603-20. 2007..The present review summarises studies into the effects of AMPA receptor potentiators (with a focus on the biarylpropylsulfonamides) in rodent models of depression and Parkinson's disease...- N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link betwMatthew J Fell
Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, DC0510, Indianapolis, IN 46285, USA
J Pharmacol Exp Ther 336:165-77. 2011..In addition, we provide evidence that sleep EEG and CSF t-MeHA might function as viable biomarker approaches to facilitate the translational development of THIIC and other mGlu2 potentiators... - Evaluation of blood-brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson's diseasePaulien Gm Ravenstijn
Division of Pharmacology, LACDR Leiden University, Leiden, The Netherlands
Fluids Barriers CNS 9:4. 2012..abstract:.. - SMi 4th Annual Conference on Neurodegenerative Disorders: a focus on Alzheimer's and Parkinson's diseaseMICHAEL J O'NEILL
Eli Lilly and Co Ltd, Erl Wood Manor, Windlesham, Surrey, UK
Expert Opin Investig Drugs 13:1369-73. 2004..g., glial cell line-derived neurotrophic factor) and mixed lineage/c-Jun N-terminal kinase inhibitors, such as CEP-1347. Small molecules that enhance endogenous signalling and repair pathways were also discussed... - AMPA receptor potentiators for the treatment of CNS disordersMICHAEL J O'NEILL
Eli Lilly and Co Ltd, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK
Curr Drug Targets CNS Neurol Disord 3:181-94. 2004.... - Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's diseaseMICHAEL J O'NEILL
Eli Lilly and Co Ltd, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK
Eur J Pharmacol 486:163-74. 2004..Therefore, we propose that AMPA receptor potentiators offer the potential of a new therapy to halt the progression and perhaps repair the degeneration in Parkinson's disease... - AMPA receptor potentiators as cognitive enhancersMICHAEL J O'NEILL
Eli Lilly and Co Ltd, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK
IDrugs 10:185-92. 2007..Nevertheless, boosting Ca(2+) flux through the AMPA receptor, and enhancing LTP and downstream pathways may provide a novel approach to the treatment of cognitive deficits... - The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegenerationM J O'Neill
Eli Lilly and Co Ltd, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK
Curr Drug Targets CNS Neurol Disord 1:399-411. 2002.... - LY393615, a novel neuronal Ca(2+) and Na(+) channel blocker with neuroprotective effects in models of in vitro and in vivo cerebral ischemiaM J O'Neill
Lilly Research Centre Ltd, Erl Wood Manor, Windlesham, GU20 6PH, Surrey, UK
Brain Res 888:138-149. 2001..The compound is neuroprotective when administered post-occlusion and may therefore be a useful anti-ischaemic agent... - ARL 17477, a selective nitric oxide synthase inhibitor, with neuroprotective effects in animal models of global and focal cerebral ischaemiaM J O'Neill
Eli Lilly and Co Ltd, Lilly Research Centre, Erl Wood Manor, Windlesham, GU20 6PH, Surrey, UK
Brain Res 871:234-44. 2000.... - LY377770, a novel iGlu5 kainate receptor antagonist with neuroprotective effects in global and focal cerebral ischaemiaM J O'Neill
Eli Lilly and Co Ltd, Lilly Research Centre, Erl Wood Manor, Windlesham, GU20 6PH, Surrey, UK
Neuropharmacology 39:1575-88. 2000..LY377770 is a novel, soluble, systemically active iGlu5 antagonist with efficacy in global and focal ischaemia, even when administered post-occlusion. LY377770 may therefore be useful as a neuroprotectant in man... - Decahydroisoquinolines: novel competitive AMPA/kainate antagonists with neuroprotective effects in global cerebral ischaemiaM J O'Neill
Lilly Research Centre, Eli Lilly and Co Ltd, Windlesham, UK
Neuropharmacology 37:1211-22. 1998..LY377770 (a mixed AMPA/iGluR5 antagonist and active isomer of LY294486) demonstrated good neuroprotection with a 2-h time window and may therefore be useful in the treatment of ischaemic conditions... - Neuroprotective effects of the antioxidant LY231617 and NO synthase inhibitors in global cerebral ischaemiaM J O'Neill
Lilly Research Centre Limited, Erl Wood Manor, Surrey, UK
Brain Res 760:170-8. 1997..Antioxidants such as LY231617 or neuronal NO synthase inhibitors can prevent the ischaemia-induced neurodegeneration and may be useful as anti-ischaemic agents... - LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's diseaseMICHAEL J O'NEILL
Eli Lilly and Co, Ltd, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK
CNS Drug Rev 11:77-96. 2005..Therefore, we propose that AMPA receptor potentiators such as LY503430 offer the potential of a new disease modifying therapy for Parkinson's disease... - Alterations in hippocampal excitability, synaptic transmission and synaptic plasticity in a neurodevelopmental model of schizophreniaThomas M Sanderson
Centre for Cognitive Neuroscience, Eli Lilly and Co, Erl Wood Manor, Windlesham GU20 6PH, UK
Neuropharmacology 62:1349-58. 2012..These findings suggest that delivering neurodevelopmental insults at E17 may offer insights into some of the physiological alterations that underlie behavioural and cognitive symptoms observed in schizophrenia... - Amphetamine promotes task-dependent recovery following focal cortical ischaemic lesions in the ratGary Gilmour
Eli Lilly and Co Ltd, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK
Behav Brain Res 165:98-109. 2005..They also demonstrate that different behavioural tasks measuring superficially similar behavioural outputs may show different sensitivities to such drug effects... - Neuroprotective effects of 7-nitroindazole in the gerbil model of global cerebral ischaemiaM J O'Neill
Lilly Research Centre Limited, Surrey, UK
Eur J Pharmacol 310:115-22. 1996..These results indicate that nitric oxide plays a role in ischaemic cell death and that selective neuronal nitric oxide synthase inhibitors can protect against ischaemic brain damage... - NAALADase (GCP II) inhibition prevents cocaine-kindled seizuresJeffrey M Witkin
Drug Development Group, Addiction Research Center, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA
Neuropharmacology 43:348-56. 2002..Similarly, acutely-administered 2-PMPA did not block cocaine seizures in fully-kindled mice. NAALADase inhibition thus provides a novel means of attenuating the development of cocaine seizure kindling... - Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depressionDonald R Gehlert
Neuroscience and Endocrine Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
J Pharmacol Exp Ther 329:429-38. 2009..Thus, GW803430 produces robust antiobesity and antidepressant-like effects in rats and mice at doses that compete for central MCHR1 in vivo. As such, MCHR1 should be considered as a promising target for future drug discovery efforts... - A parametric analysis of punishment frequency as a determinant of the response to chlordiazepoxide in the Vogel conflict test in ratsScott D Gleason
Neuroscience Discovery Research, The Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 0510, USA
Pharmacol Biochem Behav 87:380-5. 2007..Parametric variation under the Vogel conflict test may be useful in comparing the efficacy of novel approaches to the treatment of anxiety disorders... - Some contextual and historical determinants of the effects of chlordiazepoxide on punished responding of ratsJeffrey M Witkin
Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285 0510, USA
Psychopharmacology (Berl) 163:488-94. 2002..Nonetheless, the necessary and sufficient conditions for the anxiolytic-like activity in this animal model have not been fully delineated... - Constitutive deletion of the serotonin-7 (5-HT(7)) receptor decreases electrical and chemical seizure thresholdsJeffrey M Witkin
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
Epilepsy Res 75:39-45. 2007..In addition, the data suggest that the lower thresholds for seizures produced by diverse mechanisms should be taken into account when interpreting other aspects of the phenotype and behavioral pharmacology of this mouse... - Metabotropic glutamate receptors in the control of mood disordersJeffrey M Witkin
Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
CNS Neurol Disord Drug Targets 6:87-100. 2007.... - In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disordersLinda M Rorick-Kehn
Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, DC0510, Indianapolis, IN 46285, USA
Psychopharmacology (Berl) 193:121-36. 2007.... - Enhancement of antidepressant potency by a potentiator of AMPA receptorsXia Li
Neuroscience Discovery Research, Eli Lilly and Co, Lilly Research Laboratories, Corporate Center, Indianapolis, Indiana, USA
Cell Mol Neurobiol 23:419-30. 2003.... - Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in miceXia Li
Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285 0510, USA
J Pharmacol Exp Ther 319:254-9. 2006..This mechanism may not only provide a novel approach to the therapeutic management of depressive disorders but also may be useful in the augmentation of effects of traditional antidepressant agents... - A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disordersJeffrey M Witkin
Psychiatric Drug Discovery, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285 0510, USA
Trends Pharmacol Sci 26:609-17. 2005..Thus, CB1 receptor antagonism might constitute an integrated pharmacotherapeutic approach that impacts the affective, cognitive, appetitive and motivational neuronal networks involved in mood disorders... - A rapid punishment procedure for detection of anxiolytic compounds in miceJeffrey M Witkin
Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285 0510, USA
Psychopharmacology (Berl) 172:52-7. 2004..The use of mice in these tests has been limited, but the utility of this species in drug discovery and for neurobiological inquiry would benefit from a rapid, reliable method... - Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulatorFrançois Gastambide
Lilly Centre for Cognitive Neuroscience, Lilly Research Laboratories, Eli Lilly and Co Ltd, Windlesham, UK
Neuropsychopharmacology 37:1057-66. 2012..This study also illustrates the importance of studying putative cognitive enhancing drug effects in a number of models which may have implications for the future development of the compound... - The Methylazoxymethanol Acetate (MAM-E17) Rat Model: Molecular and Functional Effects in the HippocampusEva Hradetzky
1 Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK 2 Lilly Centre for Cognitive Neuroscience, Eli Lilly and Co Ltd, Windlesham, Surrey, UK
Neuropsychopharmacology 37:364-77. 2012..Thus, this study provides the first molecular evidence, combined with functional validation, that the MAM-E17 rat model reproduces hippocampal deficits relevant to the pathology of schizophrenia...